在强迫症中探索早期添加赛莱科克西布治疗:初步随机,双盲,安慰剂对照试验的结果
Shivangini Singh1, Anil Nischal1, Anuradha Nischal2
1Department of Psychiatry, King George's Medical University, Lucknow, Uttar Pradesh, India.
Journal of psychopharmacology (Oxford, England)
|November 28, 2025
概括
作为fluoxetine的补充剂,切莱科克西布在治疗强迫症 (OCD) 方面表现有前途. 这种早期干预显著改善了症状,并且耐受性很好,这表明了强迫症患者的新治疗途径.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 强迫症 (OCD) 治疗反应往往不令人满意,需要新的治疗策略.
- 神经炎症越来越被认为是强迫症病理生理学的潜在因素.
- 探索新的治疗方法对于改善强迫症患者的治疗结果至关重要.
研究的目的:
- 为了评估早期Celecoxib的临床疗效,在8周的时间内在OCD患者中添加到fluoxetine.
- 为了研究临床结果与干白素-6 (IL-6) 和来自大脑的神经营养因子 (BDNF) 的血清水平之间的关联.
主要方法:
- 这是一项随机对照试验,涉及44名未经药物治疗的强迫症患者.
- 参与者接受了fluoxetine加Celecoxib或fluoxetine加安慰剂.
- 在多个时间点使用耶鲁-布朗强迫症强迫度表 (YBOCS) 评估症状严重程度. 在基线和8周测量血清IL-6和BDNF水平.
主要成果:
- 与安慰剂组相比,Celecoxib组显示YBOCS得分的显著降低 (p ≤ 0.001).
- 在Celecoxib组 (33%) 与安慰剂组 (11.1%) 相比,观察到更高的反应率.
- 降低的YBOCS得分与塞莱科克西布组的血清IL-6水平降低正相关 (r=0.478,p=0.033).
结论:
- 早期添加Celecoxib治疗到fluoxetine似乎是一个安全和有效的策略,用于快速改善强迫症的精神病理.
- 这些发现表明,针对神经炎症可能对强迫症治疗有益.
- 需要进一步的研究来证实这些有希望的结果,并探索潜在的机制.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413
01:28Obsessive-Compulsive Disorder
489
Obsessive-compulsive disorder (OCD) is a mental health condition characterized by recurrent obsessions, compulsions, or both, which consume significant time and interfere with daily functioning. Obsessions involve persistent, intrusive, and unwanted thoughts, images, or urges that evoke anxiety. Common examples include irrational fears of contamination or harm. Compulsions are repetitive behaviors or mental acts performed to reduce the anxiety caused by obsessions. For instance, individuals...
489
01:29Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
01:29Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461